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Introduction
Bendamustine is being recently used as treatment of
chronic lymphocytic leukemia (CLL) and B-cell non-
Hodgkin lymphoma. There are just a few reported cases
of adverse reactions to bendamustine so far, none of
them with an allergological study.
Method
Patient 1
A 61-year old woman, diagnosed with B-cell CLL (B-
CLL) received bendamustine, tolerating the first cycle.
Three weeks later, 8 hours after the 1st dose of the 2nd
cycle, she suffered throat discomfort, pruritus, hives,
general erythema and facial swelling; which disappeared
within 24 hours after treatment.
Patient 2
A 61-year old man, diagnosed with B-CLL. Four years
ago, he adequately tolerated bendamustine. One week
after the first and well tolerated cycle, he received the
second, and within 8-10 hours after the dose he devel-
oped a maculopapular exanthema, edema in arms and
legs, along with desquamation of hands and feet, with-
out residual lesions. Symptoms disappeared within the
first two weeks.
Patient 3
A 63-year old man, diagnosed with B-CLL. Three hours
after the infusion of the first and second cycles of bend-
amustine, he had a generalized tremor and fever of
39℃. The symptoms ceased with acetaminophen
650mg. One month later, 3 hours after the 3rd cycle of
bendamustine, he had generalized tremor and erythema,
dizziness and body temperature of 39℃. Hypotension,
paroxysmal atrial fibrillation and a mild renal failure
were verified. The symptoms disappeared with acetami-
nophen 1gr and an adequate hydration.
Results
We performed skin-prick-test (SPT) at 1 mg/ml and
intradermal testing (IDT) at 0.001, 0.01, 0.1 and 1mg/
ml, with immediate and delayed lectures (24h and 72h).
As negative controls two B-CLL patients underwent
SPT and IDT with negative results.
Patient 1
SPT was negative. IDT at 0.1 and 1mg/ml were positive
at 24h, being negative 72h later. The rest of the tests
were negative.
Patient 2
He had a negative SPT. The 24h lectures of the IDT
were positive at 0.01, 0.1 and 1mg/ml, remaining posi-
tive 72h later. The rest of the tests were negative.
Patient 3
The SPT and IDT, both immediate and delayed lectures,
were negative.
Conclusion
We report the first two cases of hypersensitivity to
bendamustine with a positive result in the allergological
study carried out, which demonstrated a delayed cuta-
neous hypersensitivity to bendamustine. We also report
the first case of drug fever induced by bendamustine in
clinical use, showing neither a type I nor a IV hypersen-
sitivity mechanism to bendamustine.
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